Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Olmedo W, Villablanca P, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo C, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez D, Cox-Alomar P, Pyo R, Krishnan P, Wiley J. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis. Vascular 2018, 27: 78-89. PMID: 30501582, DOI: 10.1177/1708538118807522.Peer-Reviewed Original ResearchConceptsPercutaneous peripheral interventionsAccess site complicationsPeripheral interventionsCause mortalitySite complicationsMinor bleedingSystematic reviewEfficacy of bivalirudinProcedural anticoagulant agentLarge randomized trialsSignificant differencesBivalirudin useMajor bleedingIntracranial bleedingBlood transfusionRandomized trialsMyocardial infarctionAnticoagulant agentsClinical studiesBivalirudinBleedingComplicationsPatientsHeparinMortalityClinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin
Avendano R, Romero J, Lupercio F, Diaz J, Quispe R, Golive A, Natale A, Garcia M, Krumerman A, Di Biase L. Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. Journal Of Interventional Cardiac Electrophysiology 2018, 54: 73-80. PMID: 30128801, DOI: 10.1007/s10840-018-0427-y.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsMajor bleedingAtrial fibrillationThromboembolic eventsIntracranial bleedingClinical outcomesRisk ratioStroke/thromboembolic eventsRecent retrospective trialsMantel-Haenszel methodConclusionAmong patientsTE preventionOral anticoagulantsIncreased riskRetrospective trialsResultsA totalHigh riskAmiodaroneBleedingPatientsWarfarinSystematic reviewP-glycoproteinConfidence intervalsOutcomes